U.S. Markets closed

Why Keytruda Could Boost Merck’s Revenue Growth in 2018

Daniel Collins

In September 2017, the FDA approved Merck’s (MRK) Keytruda for the treatment of individuals with relapsing or recurrent metastatic GEJ (gastroesophageal junction) adenocarcinoma with PDL11-expressing tumors, ...